Skip to Main Content

Paper Details

Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.
Diabetes Obes Metab
1
2023
Author NameAffiliation
Deepak L BhattIcahn School of Medicine at Mount Sinai Health System
David Z I CherneyUniversity of Toronto
Christopher P CannonBrigham and Women's Hospital, Harvard Medical School
  • 1 - 3

Datasets

Release 1.2